Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.71 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.71 |
| ▸ | ABL1 | P00519 | 3/20 | 0.64 |
| ▸ | BCR | P11274 | 3/20 | 0.64 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | PHGDH | O43175 | 1/20 | 0.54 |
| ▸ | HTR2B | P41595 | 1/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.53 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nicopholine SCHEMBL11483977 | 0.84 | PKM (0.61) | HPGDALDH1A1MAPTMEN1KMT2A | |
| Nicopholine SCHEMBL29915283 | 0.84 | PKM (0.61) | HPGDALDH1A1MAPTMEN1KMT2A | |
| Nicopholine SCHEMBL967933 | 0.84 | PKM (0.61) | HPGDALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL8150805 | 0.84 | HPGD (0.76) | HPGDALDH1A1PHGDHSLC6A7MAPT | |
| SCHEMBL27857429 | 0.83 | HPGD (0.71) | RIPK1HPGDALDH1A1PHGDHMEN1 | |
| SCHEMBL3585560 | 0.80 | SLC6A7 (0.78) | MKNK1MKNK2ABL1BCRALDH1A1 | |
| SCHEMBL31699695 | 0.79 | ALDH1A1 (0.56) | HPGDALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL31428744 | 0.79 | HPGD (0.53) | MKNK1MKNK2ABL1BCRRIPK1 | |
| SCHEMBL15754906 | 0.78 | PHGDH (0.66) | HPGDALDH1A1PHGDHMAPTKMT2A | |
| SCHEMBL11992445 | 0.78 | CYP11B2 (0.55) | MKNK1MKNK2HPGDALDH1A1PHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181596-A1 | Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain Cancer | SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (KR) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181596-A1 | Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain Cancer | LRRK2, FABP7, PARK7 | MKNK1 722/4885MKNK2 549/4885ABL1 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.